Annovex Pharma, Inc.
FDA 503B outsourcing facility
Lorton, Virginia
Key Takeaways
- FDA-registered 503B outsourcing facility since 2021
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: June 3, 2026
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- October 14, 2021
- Most recent registration
- February 13, 2026
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- June 3, 2026
- NPI
- 1124704044
The FDA last inspected Annovex Pharma, Inc. on June 3, 2026. Investigators issued a Form FDA 483 listing inspectional observations at that visit. The FDA has not yet determined whether further action will be taken.
What this facility compounds
Annovex Pharma, Inc. reports compounding 17 distinct active ingredients to the FDA Outsourcing Facility Product Report (most recent reporting periods).
Tracked on PeptideGrids: NAD+, Semaglutide, Tirzepatide.
- Ephedrine Sulfate
- Esmolol Hydrochloride
- Etomidate
- Heparin Sodium
- Labetalol Hydrochloride
- Lidocaine Hydrochloride
- Lorazepam
- Morphine Sulfate
- Neostigmine Methylsulfate
- Nicotinamide Adenine Dinucleotide
- Oxycodone Hydrochloride
- Phenylephrine Hydrochloride
- Rocuronium Bromide
- Semaglutide
- Sodium Chloride
- Succinylcholine Chloride
- Tirzepatide
Location
7403 LOCKPORT PL SUITE C, Lorton, VA
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Adedayo Akinbi, 1-571-642-5262. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Annovex Pharma, Inc. with the Virginia Board of Pharmacy.
503B facilities in Virginia
Frequently asked questions
Is Annovex Pharma, Inc. registered with the FDA?
Yes. Annovex Pharma, Inc. is a registered 503B outsourcing facility, first registered with the FDA on October 14, 2021 and most recently registered on February 13, 2026.
Has Annovex Pharma, Inc. been inspected by the FDA?
The FDA last inspected Annovex Pharma, Inc. on June 3, 2026. A Form FDA 483 was issued.
Has Annovex Pharma, Inc. had any FDA drug recalls?
No FDA drug recalls are matched to Annovex Pharma, Inc. in the openFDA enforcement database.
What does Annovex Pharma, Inc. compound?
Annovex Pharma, Inc. reports compounding 17 active ingredients to the FDA, including NAD+, Semaglutide, Tirzepatide.
Where is Annovex Pharma, Inc. located?
Annovex Pharma, Inc. is located in Lorton, Virginia (7403 LOCKPORT PL SUITE C).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Annovex Pharma, Inc.. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.